Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
The ongoing political conflict resulting in a delay in policy implementation is a major dampener for Q2 earnings in the Medical space.
Thermo Fisher Scientific Inc. (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
With the Covance Drug Diagnostic arm's revenue and margins projected to decline further, LabCorp???s business in Q2 might face disruption.
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
Varian Medical Systems' (VAR) oncology business strength might drive its performance in Q3.
Align Technology (ALGN) might ride high in Q2 banking on growth in the Invisalign space.
athenahealth Inc. (ATHN) is set to report second-quarter 2017 results on Jul 20.
Intuitive Surgical Inc. (ISRG) is scheduled to report second-quarter 2017 results after the closing bell on Jul 20.
Strong focus on product launch and emerging market expansion should drive Thermo Fisher (TMO) toward an earnings beat in Q2.
Thermo Fisher Scientific, Inc. (TMO) is on a healthy growth trajectory of late and has rallied 17.7% over the past three months.
Abbott Laboratories (ABT) is scheduled to report second-quarter 2017 results before the opening bell on Jul 20.
Share price of Thermo Fisher Scientific Inc. (TMO), headquartered in Waltham, MA, scaled a new 52-week high of $177.99 on Jul 7, eventually closing a shade lower at $177.49.
http://www.weforum.org/ Precision medicine has the potential to change the way we treat and cure disease. As genomic technologies move from lab to clinic, how can precision medicine be both accessible to and affordable for all? Speakers: - Victor Dzau, President, National Academy of Medicine, USA - Carl-Henrik Heldin, Professor of Molecular Cell Biology, Uppsala University, Sweden - Gianluca Pettiti, President, Greater China, Thermo Fisher Scientific (China), People's Republic of China - Vivian Tan, Vice-President, Strategy and Transformation, Kaiser Permanente, USA - Jeroen Tas, Chief Innovation and Strategy Officer, Royal Philips, Netherlands Moderated by: - Vivienne Parry, Head of Engagement, Genomics England, United Kingdom